These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34654988)

  • 1. ASO Author Reflections: Germline Testing for All Patients With Breast Cancer: Has the Time Finally Come?
    Mittal A; Pramanik R
    Ann Surg Oncol; 2022 Feb; 29(2):1433-1434. PubMed ID: 34654988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center.
    Mittal A; Deo SVS; Gogia A; Batra A; Kumar A; Bhoriwal S; Deb KS; Dhamija E; Thulkar S; Ramprasad VL; Olopade O; Pramanik R
    Ann Surg Oncol; 2022 Feb; 29(2):1423-1432. PubMed ID: 34601666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
    Riahi A; Chabouni-Bouhamed H; Kharrat M
    Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
    Lertwilaiwittaya P; Roothumnong E; Nakthong P; Dungort P; Meesamarnpong C; Tansa-Nga W; Pongsuktavorn K; Wiboonthanasarn S; Tititumjariya W; Thongnoppakhun W; Chanprasert S; Limwongse C; Pithukpakorn M
    Breast Cancer Res Treat; 2021 Jul; 188(1):237-248. PubMed ID: 33649982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
    BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of hereditary/familial breast cancer patients with multigene targeted next generation sequencing panel and MLPA analysis in Turkey.
    Bora E; Caglayan AO; Koc A; Cankaya T; Ozkalayci H; Kocabey M; Kemer D; Aksoy S; Alicikus ZA; Akin IB; Durak MG; Gurel D; Yavuzsen T; Sevinc A; Somali I; Gorken I; Balci P; Karaoglu A; Saydam S; Ulgenalp A
    Cancer Genet; 2022 Apr; 262-263():118-133. PubMed ID: 35220195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
    Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
    JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer.
    Kwong A; Chen J; Shin VY; Ho JC; Law FB; Au CH; Chan TL; Ma ES; Ford JM
    Cancer Genet; 2015 Sep; 208(9):448-54. PubMed ID: 26271414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
    Apostolou P; Fostira F; Kouroussis C; Kalfakakou D; Delimitsou A; Agelaki S; Androulakis N; Christodoulou C; Kalbakis K; Kalykaki A; Sanidas E; Papadimitriou C; Vamvakas L; Georgoulias V; Mavroudis D; Yannoukakos D; Konstantopoulou I; Saloustros E
    Int J Cancer; 2020 Sep; 147(5):1334-1342. PubMed ID: 32022259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NCCN Criterion "Young Age at Onset" Alone is Not an Indicator of Hereditary Breast Cancer in Iranian Population.
    Ebrahimi E; Sellars E; Shirkoohi R; Harirchi I; Ghiasvand R; Mohebbi E; Zendehdel K; Akbari MR
    Cancer Prev Res (Phila); 2019 Nov; 12(11):763-770. PubMed ID: 31451522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
    Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N
    Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genetics of hereditary cancer risk syndromes in Brazil: a comprehensive analysis of 1682 patients.
    de Oliveira JM; Zurro NB; Coelho AVC; Caraciolo MP; de Alexandre RB; Cervato MC; Minillo RM; de Vasconcelos Carvalho Neto G; Grivicich I; Oliveira JB
    Eur J Hum Genet; 2022 Jul; 30(7):818-823. PubMed ID: 35534704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
    PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
    Nilsson MP; Törngren T; Henriksson K; Kristoffersson U; Kvist A; Silfverberg B; Borg Å; Loman N
    Breast Cancer Res Treat; 2018 Feb; 168(1):117-126. PubMed ID: 29164420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.
    Singh J; Thota N; Singh S; Padhi S; Mohan P; Deshwal S; Sur S; Ghosh M; Agarwal A; Sarin R; Ahmed R; Almel S; Chakraborti B; Raina V; DadiReddy PK; Smruti BK; Rajappa S; Dodagoudar C; Aggarwal S; Singhal M; Joshi A; Kumar R; Kumar A; Mishra DK; Arora N; Karaba A; Sankaran S; Katragadda S; Ghosh A; Veeramachaneni V; Hariharan R; Mannan AU
    Breast Cancer Res Treat; 2018 Jul; 170(1):189-196. PubMed ID: 29470806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.